EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PharmaEssentia's Enterprise Value is €5,162.1 Mil.
PharmaEssentia's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €93.1 Mil. Therefore, PharmaEssentia's EV-to-FCF for today is 55.46.
The historical rank and industry rank for PharmaEssentia's EV-to-FCF or its related term are showing as below:
FRA:8Z1'
s EV-to-FCF Range Over the Past 10 Years
Min: -1449.22 Med: -35 Max: 484.59
Current: 148.05
During the past 13 years, the highest EV-to-FCF of PharmaEssentia was 484.59. The lowest was -1449.22. And the median was -35.00.
FRA:8Z1's EV-to-FCF is ranked worse than 90.59% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs FRA:8Z1: 148.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaEssentia's PE Ratio (TTM) for today is calculated as:
PharmaEssentia's share price for today is €15.50.
PharmaEssentia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.381.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PharmaEssentia EV-to-FCF Related Terms
PharmaEssentia EV-to-FCF Historical Data
* Premium members only.
The historical data trend for PharmaEssentia's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaEssentia's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEssentia EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaEssentia's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PharmaEssentia's EV-to-FCF falls into.
PharmaEssentia's current Enterprise Value is €5,162.1 Mil.
PharmaEssentia's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €93.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaEssentia (FRA:8Z1) has a EV-to-FCF of 55.46 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmaEssentia and its competitors. According to the industry distribution chart, PharmaEssentia ranks #510 out of 563 companies in the Drug Manufacturers industry, placing it in the top 90.6%.
Is PharmaEssentia's EV-to-FCF too high?
PharmaEssentia's current EV-to-FCF is 55.46. The Drug Manufacturers industry median EV-to-FCF is 20.85. PharmaEssentia's value of 55.46 is 166% above this industry median. Based on the distribution chart, PharmaEssentia ranks #510 out of 563 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PharmaEssentia has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does PharmaEssentia's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaEssentia ranks #510 out of 563 companies for EV-to-FCF. This places PharmaEssentia in the lower half of its industry. The industry median EV-to-FCF is 20.85. PharmaEssentia's value of 55.46 is 166% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaEssentia's current EV-to-FCF of 55.46 is 166% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmaEssentia and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaEssentia's current EV-to-FCF is 55.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEssentia stock overvalued right now?
PharmaEssentia (FRA:8Z1) has a current EV-to-FCF of 55.46. The stock's GF Value™ is €14.98, compared to a current price of €15.50 — trading 3.5% above its estimated fair value. The current EV-to-FCF is 55.46 and 166% above the Drug Manufacturers industry median of 20.85. PharmaEssentia's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PharmaEssentia (FRA:8Z1), the current EV-to-FCF is 55.46 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEssentia (FRA:8Z1) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEssentia stock appears to be overvalued.
The current stock price of €15.50 is trading 3.5% above its estimated GF Value™ of €14.98.
Key valuation signals for FRA:8Z1:
EV-to-FCF: 55.46
GF Value™: €14.98 vs. price of €15.50 (3.5% above fair value)
Industry Position: 166% above the Drug Manufacturers median (#510 of 563)
No single metric tells the full story. See the FRA:8Z1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEssentia Corp engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API and new drug patterns developments. Its products include BESREMi, Ropeginterferon alfa-2b, Ropeg + anti PD-1, PEG-IL-2, PEG-Cytokines, PD-1-IL-2v, NY-ESO-1 TCR-T, among others. It derives revenue from medicine products sales from contracts with customers.
82GF Score
Get the complete analysis for FRA:8Z1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8Z1 has been successfully added to your 
